Loading...
XMEX
LABB
Market cap1.12bUSD
Apr 11, Last price  
22.75MXN
1D
-1.98%
1Q
-13.73%
Jan 2017
5.72%
IPO
175.26%
Name

Genomma Lab Internacional SAB de CV

Chart & Performance

D1W1MN
P/E
10.64
P/S
1.22
EPS
2.14
Div Yield, %
3.48%
Shrs. gr., 5y
-1.38%
Rev. gr., 5y
7.92%
Revenues
18.61b
+12.99%
692,666,0001,373,480,0001,872,863,0002,629,430,0004,424,655,0006,263,621,0008,074,787,0009,799,690,00011,360,689,00011,540,998,00011,042,452,00011,316,310,00012,078,443,00011,794,419,00012,712,890,00013,870,148,00015,487,059,00016,819,912,00016,467,126,00018,606,903,000
Net income
2.14b
+97.00%
-114,344,000180,301,000304,399,000515,776,000760,036,0001,092,958,0001,415,954,0001,504,004,0001,760,607,0001,444,558,000-1,068,519,000-1,680,925,0001,279,208,0001,109,465,000764,463,0001,403,503,0001,307,867,0001,389,203,0001,084,915,0002,137,304,000
CFO
3.02b
+34.44%
-101,407,000103,331,000228,892,000385,519,000849,667,00089,212,000-107,086,0001,870,747,0001,038,596,000322,300,0001,674,845,0001,420,074,0001,562,479,0001,006,931,0001,714,525,0001,468,351,0002,054,793,0002,247,012,0003,020,990,000
Dividend
Sep 13, 20240.2 MXN/sh
Earnings
Apr 22, 2025

Profile

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
URL
http://www.genommalab.com/mx/
IPO date
Jun 19, 2008
Employees
2,388
Domiciled in
MX
Incorporated in
MX

Valuation

Title
MXN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
18,606,903
12.99%
16,467,126
-2.10%
16,819,912
8.61%
Cost of revenue
14,323,108
13,222,085
13,578,678
Unusual Expense (Income)
NOPBT
4,283,795
3,245,041
3,241,234
NOPBT Margin
23.02%
19.71%
19.27%
Operating Taxes
753,777
635,674
867,609
Tax Rate
17.60%
19.59%
26.77%
NOPAT
3,530,018
2,609,367
2,373,625
Net income
2,137,304
97.00%
1,084,915
-21.90%
1,389,203
6.22%
Dividends
(778,819)
(580,704)
(777,663)
Dividend yield
3.25%
4.29%
4.64%
Proceeds from repurchase of equity
11,107
(162,266)
(523,774)
BB yield
-0.05%
1.20%
3.13%
Debt
Debt current
2,005,294
4,851,497
Long-term debt
5,064,810
4,280,974
1,653,390
Deferred revenue
Other long-term liabilities
676,044
114,495
115,077
Net debt
2,685,698
4,085,019
4,220,579
Cash flow
Cash from operating activities
3,020,990
2,247,012
2,054,793
CAPEX
(227,523)
(19,473)
Cash from investing activities
(813,225)
(302,210)
(282,297)
Cash from financing activities
(1,591,041)
(1,676,821)
(1,362,397)
FCF
5,031,287
(3,103,113)
1,715,236
Balance
Cash
2,379,112
1,655,328
1,496,556
Long term investments
545,921
787,752
Excess cash
1,448,767
1,377,893
1,443,312
Stockholders' equity
14,039,818
12,687,251
11,958,795
Invested Capital
15,880,681
14,417,174
14,229,327
ROIC
23.30%
18.22%
16.78%
ROCE
24.72%
20.13%
20.18%
EV
Common stock shares outstanding
944,862
957,344
993,229
Price
25.34
79.21%
14.14
-16.18%
16.87
-21.46%
Market cap
23,942,800
76.87%
13,536,844
-19.21%
16,755,773
-22.58%
EV
26,628,498
17,621,863
20,976,352
EBITDA
4,643,381
3,472,344
3,468,359
EV/EBITDA
5.73
5.07
6.05
Interest
887,799
829,903
525,641
Interest/NOPBT
20.72%
25.57%
16.22%